Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer. Padda, S., Brzezniak, C. E., Waqar, S., Wakelee, H. A., Ma, P. C., Rose, M. G., Reid, T., Spira, A. I., Wong, E., Zeman, K., Oronsky, B., Abrouk, N. D., Morgensztern, D. AMER SOC CLINICAL ONCOLOGY. 2018
View details for DOI 10.1200/JCO.2018.36.15_suppl.e20575
View details for Web of Science ID 000442916006474